Real-time Estimate
Cboe BZX
03:32:36 2024-05-20 pm EDT
|
5-day change
|
1st Jan Change
|
6.955
USD
|
-9.08%
|
|
-19.29%
|
+38.75%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,419
|
2,076
|
3,352
|
5,290
|
-
|
-
|
Enterprise Value (EV)
1 |
2,419
|
2,076
|
3,352
|
5,290
|
5,290
|
5,290
|
P/E ratio
|
-6.83
x
|
-4.88
x
|
-4.37
x
|
-9.11
x
|
-15.1
x
|
255
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2,590
x
|
8,648
x
|
5,389
x
|
49.1
x
|
19.1
x
|
10.2
x
|
EV / Revenue
|
2,590
x
|
8,648
x
|
5,389
x
|
49.1
x
|
19.1
x
|
10.2
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-7.85
x
|
-4.99
x
|
-
|
-17.1
x
|
-29.2
x
|
96.2
x
|
FCF Yield
|
-12.7%
|
-20%
|
-
|
-5.86%
|
-3.42%
|
1.04%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
397,800
|
409,395
|
667,705
|
691,568
|
-
|
-
|
Reference price
2 |
6.080
|
5.070
|
5.020
|
7.650
|
7.650
|
7.650
|
Announcement Date
|
3/1/22
|
3/1/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.934
|
0.24
|
0.622
|
107.8
|
277.4
|
521.2
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-330.3
|
-351.3
|
-362.2
|
-308.4
|
-172.6
|
16.18
|
Operating Margin
|
-35,361.88%
|
-146,374.17%
|
-58,239.55%
|
-286.09%
|
-62.22%
|
3.1%
|
Earnings before Tax (EBT)
1 |
-349.8
|
-417.3
|
-583.9
|
-439.1
|
-308.2
|
-81.22
|
Net income
1 |
-346.8
|
-416.6
|
-583.2
|
-436.9
|
-306.5
|
-80.27
|
Net margin
|
-37,129.55%
|
-173,569.58%
|
-93,761.41%
|
-405.26%
|
-110.5%
|
-15.4%
|
EPS
2 |
-0.8900
|
-1.040
|
-1.150
|
-0.8400
|
-0.5050
|
0.0300
|
Free Cash Flow
1 |
-308
|
-415.7
|
-
|
-310
|
-181
|
55
|
FCF margin
|
-32,974.52%
|
-173,196.25%
|
-
|
-287.57%
|
-65.25%
|
10.55%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/1/22
|
3/1/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.39
|
0.014
|
0.035
|
0.118
|
0.073
|
0.36
|
0.041
|
0.082
|
0.139
|
0.04
|
2.525
|
10.02
|
22.74
|
35.02
|
55.02
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-79.27
|
-95.97
|
-
|
-90.8
|
-84.9
|
-111.6
|
-85.14
|
-80.14
|
-85.39
|
-95.2
|
-90.91
|
-85.72
|
-78.68
|
-68.6
|
-52.1
|
Operating Margin
|
-20,326.67%
|
-685,514.29%
|
-
|
-76,952.54%
|
-116,301.37%
|
-30,994.44%
|
-207,670.73%
|
-97,726.83%
|
-61,430.94%
|
-237,990%
|
-3,600.51%
|
-855.11%
|
-346.03%
|
-195.86%
|
-94.68%
|
Earnings before Tax (EBT)
1 |
-91.55
|
-103
|
-
|
-111.2
|
-108.3
|
-116.6
|
-138.2
|
-95.64
|
-233.5
|
-134.1
|
-114.6
|
-109.4
|
-102.7
|
-92.99
|
-76.74
|
Net income
1 |
-91.26
|
-102.8
|
-
|
-110.9
|
-108.2
|
-116.3
|
-137.9
|
-95.58
|
-233.4
|
-134.1
|
-114.6
|
-109.4
|
-102.7
|
-92.99
|
-76.74
|
Net margin
|
-23,399.74%
|
-734,471.43%
|
-
|
-94,015.25%
|
-148,239.73%
|
-32,317.5%
|
-336,290.24%
|
-116,563.41%
|
-167,907.91%
|
-335,272.5%
|
-4,539.29%
|
-1,090.81%
|
-451.7%
|
-265.49%
|
-139.46%
|
EPS
2 |
-0.2300
|
-0.2600
|
-0.2400
|
-0.2800
|
-0.2700
|
-0.2700
|
-0.3200
|
-0.1900
|
-0.3800
|
-0.2000
|
-0.1500
|
-0.1500
|
-0.1400
|
-0.1400
|
-0.1100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/1/22
|
5/10/22
|
8/8/22
|
11/9/22
|
3/1/23
|
5/11/23
|
8/8/23
|
11/9/23
|
3/19/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-308
|
-416
|
-
|
-310
|
-181
|
55
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
78.2
|
-
|
50
|
50
|
50
|
Capex / Sales
|
-
|
32,567.5%
|
-
|
46.38%
|
18.03%
|
9.59%
|
Announcement Date
|
3/1/22
|
3/1/23
|
3/19/24
|
-
|
-
|
-
|
Last Close Price
7.65
USD Average target price
7.5
USD Spread / Average Target -1.96% Consensus |
1st Jan change
|
Capi.
|
---|
| +38.75% | 5.29B | | +9.75% | 115B | | +12.14% | 106B | | -2.59% | 21.96B | | -12.40% | 21.87B | | -5.29% | 19.21B | | -3.52% | 18.08B | | -38.57% | 17.71B | | +6.99% | 14.32B | | +35.76% | 12.42B |
Bio Therapeutic Drugs
|